(Reuters)—Malaria drug hydroxychloroquine (HCQ), which U.S. President Donald Trump says he has been taking, is tied to increased risk of death in COVID-19 patients, according to a study published in The Lancet.1 The registry analysis, which included data from 671 hospitals in six continents and over 96,000 patients hospitalized with COVID-19, showed that people treated…
U.K. Healthcare Workers Begin COVID-19 HCQ Trial
LONDON (Reuters)—On May 21, British healthcare workers began taking part in a University of Oxford-led international trial of two anti-malarial drugs to see if they can prevent COVID-19, including one U.S. President Donald Trump says he has been taking. The COPCOV study will involve more than 40,000 frontline healthcare workers from Europe, Africa, Asia and…
Rheumatology Education Goes ViRL: New Online Courses Use Interactive Platforms to Engage Fellows
Interactive rheumatology education has flourished online thanks to grassroots efforts & ACR support…
Seronegative RA May Be on the Rise
A study comparing trends in the incidence of RA from 2005 to 2014 with previous decades showed a shift in RA subset, suggesting the need for timely recognition of rheumatoid factor-negative RA…
Clinical Criteria for RA & Early Non-Response to Certolizumab as Predictors of Patient Outcomes
A recent study compared three clinical criteria for rheumatoid arthritis (RA) in patients using certolizumab, assessing the predictability of treatment non-response. Researchers found Clinical Disease Activity Index measurement at three months may predict patient outcomes at 12 months…
RheumPAC Hosts Rep. Ami Bera (D-Calif.) for Virtual Discussion of ACR Legislative Priorities
Top RheumPAC donors attended a virtual legislative update and Q&A with Rep. Ami Bera (D-Calif.) shortly after the release of House Democrats’ $3 trillion coronavirus response plan.
AMA House of Delegates Meeting Postponed Due to COVID-19, Advocacy Efforts Continue
Due to the COVID-19 pandemic, the AMA House of Delegates meeting planned for June has been canceled, but the ACR’s delegation remains ready to advocate for both ongoing and new rheumatology issues, including patient protections in step therapy, prior authorization and expansion of telehealth.
Driving through the Storm: A Pediatric Rheumatologist Finds a Pandemic of Rheumatic Disease
A pediatric rheumatologist in the thick of treating children with COVID-19 confronts a new and evolving syndrome.
Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions
At the Loma Linda University Medical Center, Calif., rheumatologists play a key consulting role for COVID-19 patients who may benefit from the use of biologic treatments…
Fellowship Training Goes Virtual: COVID-19 Pandemic Creates Training Challenges
With telemedicine platforms and Zoom calls, technology is playing a large role in how rheumatology fellows are seeing patients and participating in lectures and conferences…
- « Previous Page
- 1
- …
- 195
- 196
- 197
- 198
- 199
- …
- 811
- Next Page »